Arch Immunol Ther Exp (Warsz) 2000, 48:31–38. 5. Weber-Dąbrowska B, Zimecki M, Mulczyk M, Górski A: Effect of phage therapy on the turnover and function of peripheral neutrophils. FEMS Immunol Med Microb 2002, 34:135–138.CrossRef 6. Międzybrodzki R, Świtała-Jeleń K, Fortuna W, Weber-Dąbrowska B, Przerwa A, Łusiak-Szelachowska M, Dąbrowska K, Kurzepa A, Boratyński J, Syper D, Poźniak G, Ługowski C, Górski A: Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated
polymorphonuclear leukocytes. Virus Res 2008, 131:233–242.CrossRefPubMed 7. Przerwa A, Zimecki M, Świtała-Jeleń K, Dąbrowska K, Krawczyk selleck products E, Łuczak M, Weber-Dąbrowska B, Syper D, Międzybrodzki R, Górski selleckchem A: Effects of bacteriophages on free radical production and phagocytic fuctions.
Med Microbiol Immunol 2005, 195:143–150.CrossRef 8. Dąbrowska K, Opolski A, Wietrzyk J, Świtała-Jeleń K, Godlewska J, Boratyński J, Syper D, Weber-Dąbrowska B, Górski A: Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res 2004, 24:3991–3995.PubMed 9. Levin BR, Bull JJ: Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2004, 2:166–173.CrossRefPubMed 10. Kucharewicz-Krukowska A, Ślopek S: Immunogenic effect of bacteriophages in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987, 35:553–561. 11. Bucknall R, Leirisalo-repo M, Laitinen 0, Jones JV: Antibody producing capacity to the bacteriophage phi X174 in yersinia arthritis. Ann Rheum Dis 1987, 46:883–888.CrossRefPubMed 12. Ackermann HW, Dubow MS: Viruses of prokaryotes. General properties of bacteriophages CRC Press Boca Raton, FL 1987, 1:49–76. 13. Koga T, Toyoshima
S, Kawata T: Morphological varieties and host rouge of vibrio parahaemolyticus bacteriophages isolated from sea water. Appl Environ Microbiol 1982, 44:466–470.PubMed 14. Sulakvelidze A, Morris JG: Bacteriophage therapy. Antimicrob Agents LY294002 Chemother 2001, 45:649–659.CrossRefPubMed 15. Broudy TB, Fischetti VA: In vivo lysogenic conversion of Tox (-) Streptococcus pyogenes to Tox (+) with lysogenic Streptococcus or free phage. Infect Immun 2003, 71:3782–3786.CrossRefPubMed 16. Borysowski J, Górski A: Is phage therapy acceptable in the immunocompromised host? Int J Infect Dis 2008, 12:466–471.CrossRefPubMed 17. Weber-Dąbrowska B, Mulczyk M, Górski A: Bacteriophage therapy for infections in cancer patients. Clin Appl Immunol Rev 2001, 1:131–134.CrossRef 18. Górski A, Borysowski J, Międzybrodzki R, Weber-Dąbrowska B: Bacteriophages in Medicine. Bacteriophage: Genetics and Molecular Biology (Edited by: Mc Grath S, van Sinderen D). Mocetinostat Norfolk: Caister Academic Press 2007, 125–158. 19. Górski A, Kniotek M, Perkowska-Ptasińska A, Mróz A, Przerwa A, Gorczyca W, Dąbrowska K, Weber-Dąbrowska B, Nowaczyk M: Bacteriophages and transplantation tolerance.